Dublin City University, Vaccinogen deal

The university granted Vaccinogen an exclusive, two-year option to evaluate and purchase the university’s DiCAST high throughput screening and analysis technology. Vaccinogen said it plans to use DiCAST to develop mAbs from patient-derived biological samples acquired after gaining anticancer immunity.

If Vaccinogen exercises its option to purchase DiCAST, the company said it may develop the technology to focus on small molecule drug discovery and other biologics, with applications for therapeutics, diagnostics and research. ...